134 results
8-K
EX-99.2
VIR
Vir Biotechnology Inc
6 Jul 20
Our mission is to create a world without infectious disease
6:32am
or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management’s attention and consumes … us to potential litigation;
business combinations or significant changes in a strategic collaborator’s business strategy may adversely affect
8-K
EX-99.1
VIR
Vir Biotechnology Inc
10 Apr 20
Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture ofSARS-COV-2 Antibodies for Potential COVID-19 Treatment
8:01am
www.vir.bio.
Vir Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation … competition, delays or
disruptions in Vir’s business or clinical trials due to theCOVID-19 pandemic, and unexpected litigation or other disputes. Other factors
8-K
EX-99.1
VIR
Vir Biotechnology Inc
23 Jan 20
Other Events
6:08am
Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words … that are lower than expected, changes in expected or existing competition, and unexpected litigation or other disputes. Other factors that may cause actual
8-K
VIR
Vir Biotechnology Inc
30 Jan 20
Other Events
6:07am
Statements
This Current Report on Form8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 … , regulatory delays and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied
8-K
EX-99.1
VIR
Vir Biotechnology Inc
29 May 20
Vir Biotechnology and Biogen Execute Agreement to ManufactureSARS-CoV-2 Antibodies for PotentialCOVID-19 Treatment
4:06pm
Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “goal,” “intend … in the Vir’s business or clinical trials due to theCOVID-19 pandemic, unexpected litigation or other disputes, challenges in neutralizingSARS-CoV-2, difficulty
8-K
azrnqvemklikw
13 Dec 23
Cost Associated with Exit or Disposal Activities
4:06pm
8-K
q3uqatm ym49qyr7o5
29 May 20
Vir Biotechnology and Biogen Execute Agreement to ManufactureSARS-CoV-2 Antibodies for PotentialCOVID-19 Treatment
4:06pm
8-K
ionfr8phsn
10 Apr 20
Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture ofSARS-COV-2 Antibodies for Potential COVID-19 Treatment
8:01am
8-K
zo5 9gq1b003h
27 May 21
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives
4:55pm
8-K
EX-99.1
ua20u
28 Jan 21
Other Events
4:05pm
10-Q
vvyro
19 Nov 19
Quarterly report
4:06pm
8-K
ad4 jwusa58
25 Mar 22
Other Events
4:10pm
8-K
5trsacz u39ei
5 Apr 22
Other Events
5:19pm
8-K
wtndvg cer6nyh
4 Oct 22
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
8:23am
8-K
EX-99.1
znqcw41qo4v
4 Oct 22
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
8:23am
8-K
EX-99.1
rx66ylx
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am